Evidence map›Paper›PMID 30633040›Full record

Trial reportJournal of acquired immune deficiency syndromes (1999)2019

Young Women's Stated Preferences for Biomedical HIV Prevention: Results of a Discrete Choice Experiment in Kenya and South Africa.

Alexandra M Minnis, Erica N Browne, Marco Boeri, Kawango Agot, Ariane van der Straten, Khatija Ahmed, Rachel Weinrib, Carol Mansfield

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of acquired immune deficiency syndromes (1999), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

87 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Article

27 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Alexandra M MinnisWomen's Global Health Imperative, RTI International, San Francisco, CA.
Erica N BrowneWomen's Global Health Imperative, RTI International, San Francisco, CA.
Marco BoeriRTI Health Solutions, Research Triangle Park, NC.
Kawango AgotImpact Research and Development Organization, Kisumu, Kenya.
Ariane van der StratenWomen's Global Health Imperative, RTI International, San Francisco, CA.
Khatija AhmedSetshaba Research Centre, Soshanguve, South Africa.
Rachel WeinribWomen's Global Health Imperative, RTI International, San Francisco, CA.
Carol MansfieldRTI Health Solutions, Research Triangle Park, NC.

Funding

Ujima Mentoring ProgramP30MH062246 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 2001 to 2026
$57.4M
NIMH NIH HHS P30 MH062246
6 · The paper itself

Abstract

backgroundIntegrating end-user perspectives into the design of new biomedical HIV prevention products is recognized as vital to informing the product development pipeline.

settingKisumu, Kenya; and Soshanguve, South Africa.

methodsWe conducted a discrete choice experiment survey with 536 women aged 18-30 years to assess preferences for hypothetical HIV prevention products characterized by the attributes of efficacy, pregnancy prevention, delivery form, dosing frequency, and side effects. Participants included product-experienced women from Tablet, Ring, Injection as Options TRIO, a cross-over clinical study evaluating 3 placebo delivery forms (oral tablets, vaginal rings, and injections), and a product-naive sample recruited from the same communities. Analyses used random parameters logit and latent class models.

resultsHIV prevention efficacy was a strong determinant of stated choice overall; however, in South Africa, delivery form was just as important, with an injection every 2-3 months most preferred and a daily oral tablet least preferred. In Kenya, product-experienced women preferred monthly injections and least preferred a monthly ring. Respondents indicated a preference for multipurpose prevention technologies that combine HIV and pregnancy protection. Latent class analyses confirmed these findings and delineated heterogeneity in preferences across subgroups defined by age, past experience with the delivery forms, and education.

conclusionsDespite an overall preference for products with high efficacy, we identified attributes salient to future uptake and use of HIV prevention products. Preferences for injectable products underscored interest in this pre-exposure prophylaxis delivery form. Likewise, the multipurpose prevention technology feature was valued in both Kenya and South Africa and most influenced interest in vaginal rings.

Indexed as

AdolescentAdultContraceptionContraceptive Devices, FemaleCross-Over StudiesFemaleHIV InfectionsHumansInjectionsKenyaPatient Acceptance of Health CarePatient PreferencePlacebosPre-Exposure ProphylaxisSouth AfricaYoung AdultPlacebos

Identifiers

PMID30633040
PMCPMC6410963

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.